Researchers have confirmed that the experimental vaccine developed by China to treat Covid-19 via the Institute of Medical Biology of the Chinese Academy of Medical Sciences has been proven safe at an early stage of clinical trials.
In a research paper published on Tuesday, the researchers said that the first phase trials conducted on 191 healthy participants between the ages of 18 and 59 years did not show severe negative reactions after receiving the trial injection vaccination, and the latest results were published on Medrxiv, a free server on The Internet is for complete manuscripts in medical and clinical sciences and related but unpublished health sciences, and what is published are tagged as “advance publications” meaning preliminary reports on trials and research that have not yet been approved by medical peer review.
According to the researchers, the most prominent negative reactions reported by the participants in the experiment were mild pain, fatigue, slight redness, itching and swelling at the injection site, and the study pointed out that the candidate vaccine caused an immune response.
According to the research paper, “All data obtained in this trial support the safety and immunity of this inactivated vaccine and are encouraging regarding further studies of its effectiveness in the future.”
China has vaccinated hundreds of thousands of essential workers and other high-risk groups with other vaccines, even as clinical trials are not fully completed, raising safety concerns among experts. Note that China has so far at least 4 experimental vaccines in the final stage of clinical trials.